Faculty

32 1a 2a

61 16

Ravi K Amaravadi, MD

Tara Miller Professor of Melanoma Research and Patient Care

7 5f

Department: Medicine

4 1 23

1f Graduate Group Affiliations 8

Cell and Molecular Biology

46 Contact information
4d

Division of Hematology Oncology
33 8 BRB - Room 852
Philadelphia, PA 19104

2e Office: 215-769-5159
30

4 3 3 1d

18 Publications
23

2f 6f

26 Search PubMed for articles c

3 2 4 b 1f

13 Education:
21 7 BA 1a (Biochemistry ) c
2d Columbia University , 1996.
21 7 MD 15 (Medicine) c
32 Johns Hopkins University , 2000.
c

3 27

Links
7b Search PubMed for articles
68 Amaravadi Lab Website
c

5 3 3 92 Permanent link
2 29

b6 > Perelman School of Medicine > Faculty > Details a

1e 1d

Description of Research Expertise

4f Autophagy, Mechanisms of Cell Death, Developmental Therapeutics
65

Description of Clinical Expertise

36 Phase I and Phase II Clinical Trials
f Melanoma
1a 29

Selected Publications

11d Crissey MAS, Versace A, Bhardwaj M, Jain V, Liu S, Singh A, Beer LA, Tang HY, Villanueva J, Gimotty PA, Xu X, Amaravadi RK.: Divergent effects of acute and chronic PPT1 inhibition in melanoma. Autophagy Feb 2025.

1cf Guo Y, Wang H, Liu S, Zhang X, Zhu X, Huang L, Zhong W, Guan L, Chen Y, Xiao M, Ou L, Yang J, Chen X, Huang AC, Mitchell T, Amaravadi R, Karakousis G, Miura J, Schuchter L, Flowers A, Zheng Q, Mou H, Gimotty P, Herlyn M, Guo W, Xu X.: Engineered extracellular vesicles with DR5 agonistic scFvs simultaneously target tumor and immunosuppressive stromal cells. Sci Adv 11: eadp9009, Jan 2025.

1bc Ma KL, Mitchell TC, Dougher M, Sharon CE, Tortorello GN, Elder DE, Morgan EE, Gimotty PA, Huang AC, Amaravadi RK, Schuchter LM, Flowers A, Miura JT, Karakousis GC, Xu X.: Tumor-Infiltrating Lymphocytes in Necrotic Tumors after Melanoma Neoadjuvant Anti-PD-1 Therapy Correlate with Pathologic Response and Recurrence-Free Survival. Clin Cancer Res 30: 4987-4994, Nov 2024.

269 Wang K, Coutifaris P, Brocks D, Wang G, Azar T, Solis S, Nandi A, Anderson S, Han N, Manne S, Kiner E, Sachar C, Lucas M, George S, Yan PK, Kier MW, Laughlin AI, Kothari S, Giles J, Mathew D, Ghinnagow R, Alanio C, Flowers A, Xu W, Tenney DJ, Xu X, Amaravadi RK, Karakousis GC, Schuchter LM, Buggert M, Oldridge D, Minn AJ, Blank C, Weber JS, Mitchell TC, Farwell MD, Herati RS, Huang AC.: Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8(+) T cells. Cancer Cell Aug 2024.

1a1 Oatman N, Gawali MV, Congrove S, Cáceres R, Sukumaran A, Gupta N, Murugesan N, Arora P, Subramanian S, Choi K, Abdel-Malek Z, Reisz JA, Stephenson D, Amaravadi R, Desai P, D'Alessandro A, Komurov K, Dasgupta B.: A Multimodal Drug-Diet-Immunotherapy Combination Restrains Melanoma Progression and Metastasis. Cancer Res 84: 2333-2351, Jul 2024.

19d Anderson TM, Chang BH, Huang AC, Xu X, Yoon D, Shang CG, Mick R, Schubert E, McGettigan S, Kreider K, Xu W, Wherry EJ, Schuchter LM, Amaravadi RK, Mitchell TC, Farwell MD.: FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma. Clin Cancer Res 30: 1758-1767, May 2024.

54b Axfors C, Schmitt AM, Janiaud P, Van't Hooft J, Abd-Elsalam S, Abdo EF, Abella BS, Akram J, Amaravadi RK, Angus DC, Arabi YM, Azhar S, Baden LR, Baker AW, Belkhir L, Benfield T, Berrevoets MAH, Chen CP, Chen TC, Cheng SH, Cheng CY, Chung WS, Cohen YZ, Cowan LN, Dalgard O, de Almeida E Val FF, de Lacerda MVG, de Melo GC, Derde L, Dubee V, Elfakir A, Gordon AC, Hernandez-Cardenas CM, Hills T, Hoepelman AIM, Huang YW, Igau B, Jin R, Jurado-Camacho F, Khan KS, Kremsner PG, Kreuels B, Kuo CY, Le T, Lin YC, Lin WP, Lin TH, Lyngbakken MN, McArthur C, McVerry BJ, Meza-Meneses P, Monteiro WM, Morpeth SC, Mourad A, Mulligan MJ, Murthy S, Naggie S, Narayanasamy S, Nichol A, Novack LA, O'Brien SM, Okeke NL, Perez L, Perez-Padilla R, Perrin L, Remigio-Luna A, Rivera-Martinez NE, Rockhold FW, Rodriguez-Llamazares S, Rolfe R, Rosa R, Røsjø H, Sampaio VS, Seto TB, Shahzad M, Soliman S, Stout JE, Thirion-Romero I, Troxel AB, Tseng TY, Turner NA, Ulrich RJ, Walsh SR, Webb SA, Weehuizen JM, Velinova M, Wong HL, Wrenn R, Zampieri FG, Zhong W, Moher D, Goodman SN, Ioannidis JPA, Hemkens LG.: Author Correction: Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nat Commun 15: 1075, Feb 2024.

1cb Sharon CE, Tortorello GN, Ma KL, Huang AC, Xu X, Giles LR, McGettigan S, Kreider K, Schuchter LM, Mathew AJ, Amaravadi RK, Gimotty PA, Miura JT, Karakousis GC, Mitchell TC.: Corrigendum to 'Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanoma': [Annals of Oncology 34 (2023) 806-812] Ann Oncol 2024.

14e Zhang W, Yang J, Wang B, Lu Y, Yang J, Zhong W, Yu Z, Qin Z, Xiao B, Wang K, Ma YY, Amaravadi R, Herlyn M, Kim J, Xu X, Guo W.: HRS mediates tumor immune evasion by regulating proteostasis-associated interferon pathway activation. Cell Rep 42: 113352, Nov 2023.

1cb Zhong W, Lu Y, Han X, Yang J, Qin Z, Zhang W, Yu Z, Wu B, Liu S, Xu W, Zheng C, Schuchter LM, Karakousis GC, Mitchell TC, Amaravadi R, Flowers AJ, Gimotty PA, Xiao M, Mills G, Herlyn M, Dong H, Mitchell MJ, Kim J, Xu X, Guo W.: Upregulation of exosome secretion from tumor-associated macrophages plays a key role in the suppression of anti-tumor immunity. Cell Rep 42: 113224, Oct 2023.

2c

7 1d

2c back to top
26 Last updated: 10/24/2025
34 The Trustees of the University of Pennsylvania c

1 49 2 2 1a 32 34